MMI raises $125M Series D to scale robotic microsurgery
What's the deal? MMI (Medical Microinstruments)Dealroom has a profile for this one. Try Dealroom →, a surgical robotics company founded near Pisa, Italy, has raised $125 million in Series D financing. Existing investor BioStar CapitalDealroom has a profile for this one. Try Dealroom → led the round, with new investors S3 VenturesDealroom has a profile for this one. Try Dealroom →, Angelini VenturesDealroom has a profile for this one. Try Dealroom →, and an undisclosed strategic corporate investor participating.
What's the endgame? MMI builds the Symani Surgical System, a platform pairing the world's smallest wristed microinstruments with tremor-reducing and motion-scaling technology. It targets microvascular, lymphatic, and nerve repair in delicate cancer and trauma reconstructive surgery.
Why now? The company has roughly 50 installed systems and 3,500 complex procedures performed worldwide. The capital funds commercial expansion in the US and key markets, plus clinical trials and outcomes data, including the REMIND study.
What's next? "We've proven there is demand for robotic microsurgery at leading institutions around the world. Now, our focus is translating that adoption into scale," said chief executive officer Mark Toland. He pointed to new work in energy instruments and digital surgery, and research into Alzheimer's disease through REMIND.
The signal: At $125 million, this is one of the largest Series D rounds for an Italian health company, ranking above roughly 90% of comparable deals. BioStar founder Louie Cannon called the oversubscribed round "a transformational medical technology with the potential to revolutionize patient care" — a sign that investor appetite for robotic microsurgery is broadening beyond early adopters.
Read more: markets.financialcontent.com
Image credit: NavyMedicine
